文献速递儿童青少年精神

NKCC1抑制剂布美他尼恢复新生期脆性X小鼠皮层前馈抑制并减轻感觉超敏

The NKCC1 Inhibitor Bumetanide Restores Cortical Feedforward Inhibition and Lessens Sensory Hypersensitivity in Early Postnatal Fragile X Mice.
PubMed 文献 · Biol Psychiatry · 2024-06-29

在Fmr1敲除脆性X综合征小鼠模型中,急性布美他尼逆转出生后第6天S1区2/3层锥体神经元同步事件频率增高,慢性布美他尼(出生后5-14天)恢复S1环路差异、改善触觉防御并纠正前馈抑制及小清蛋白中间神经元参与。

要点

  • Fmr1敲除小鼠出生后第6天S1区2/3层锥体神经元同步事件频率高于野生型对照,急性布美他尼可逆转。
  • 慢性布美他尼(出生后5-14天)恢复S1环路差异,包括重复触须刺激的神经元适应降低。
  • 慢性布美他尼改善触觉防御,纠正S1区2/3层神经元前馈抑制降低并提升小清蛋白中间神经元环路参与。

核心结论

  • 突触、环路和感觉行为表型在Fmr1敲除小鼠中可被NKCC1抑制剂(如美国食品药品监督管理局批准的利尿剂布美他尼)减轻。

研究设计与样本

  • 在Fmr1敲除小鼠中采用急性和慢性全身给予布美他尼,并进行体内双光子钙成像记录神经元活动,同时用高分辨率视频追踪小鼠行为。

主要发现

  • Fmr1敲除小鼠S1区2/3层锥体神经元在出生后第6天同步事件频率高于野生型对照,急性布美他尼可逆转该差异。
  • 慢性布美他尼治疗(出生后5-14天)恢复Fmr1敲除小鼠S1环路差异,包括重复触须刺激的神经元适应降低,并改善触觉防御。
  • 布美他尼治疗纠正S1区2/3层神经元前馈抑制降低,并提升小清蛋白中间神经元的环路参与。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Exaggerated responses to sensory stimuli, a hallmark of fragile X syndrome, contribute to anxiety and learning challenges. Sensory hypersensitivity is recapitulated in the Fmr1 knockout (KO) mouse model of fragile X syndrome. Recent studies in Fmr1 KO mice have demonstrated differences in the activity of cortical interneurons and a delayed switch in the polarity of GABA (gamma-aminobutyric acid) signaling during development. Previously, we reported that blocking the chloride transporter NKCC1 with the diuretic bumetanide could rescue synaptic circuit phenotypes in the primary somatosensory cortex (S1) of Fmr1 KO mice. However, it remains unknown whether bumetanide can rescue earlier circuit phenotypes or sensory hypersensitivity in Fmr1 KO mice. METHODS: We used acute and chronic systemic administration of bumetanide in Fmr1 KO mice and performed in vivo 2-photon calcium imaging to record neuronal activity, while tracking mouse behavior with high-resolution videos. RESULTS: We demonstrated that layer 2/3 pyramidal neurons in the S1 of Fmr1 KO mice showed a higher frequency of synchronous events on postnatal day 6 than wild-type controls. This was reversed by acute administration of bumetanide. Furthermore, chronic bumetanide treatment (postnatal days 5-14) restored S1 circuit differences in Fmr1 KO mice, including reduced neuronal adaptation to repetitive whisker stimulation, and ameliorated tactile defensiveness. Bumetanide treatment also rectified the reduced feedforward inhibition of layer 2/3 neurons in the S1 and boosted the circuit participation of parvalbumin interneurons. CONCLUSIONS: This further supports the notion that synaptic, circuit, and sensory behavioral phenotypes in Fmr1 KO can be mitigated by inhibitors of NKCC1, such as the Food and Drug Administration-approved diuretic bumetanide.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kourdougli N, Nomura T, Wu MW, et al. The NKCC1 Inhibitor Bumetanide Restores Cortical Feedforward Inhibition and Lessens Sensory Hypersensitivity in Early Postnatal Fragile X Mice. Biol Psychiatry. 2024. PMID: 38950809. doi:10.1016/j.biopsych.2024.06.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。